ClinicalTrials.gov record
Completed Phase 4 Interventional

Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)

ClinicalTrials.gov ID: NCT05772169

Public ClinicalTrials.gov record NCT05772169. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 19, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Study of Hypercortisolism in Patients With Difficult to Control Type 2 Diabetes Despite Receiving Standard-of-Care Therapies: Prevalence and Treatment With Korlym® (Mifepristone) (CATALYST)

Study identification

NCT ID
NCT05772169
Recruitment status
Completed
Study type
Interventional
Phase
Phase 4
Lead sponsor
Corcept Therapeutics
Industry
Enrollment
1,113 participants

Conditions and interventions

Interventions

  • Mifepristone 300 MG [Korlym] Drug
  • Placebo for mifepristone Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 80 Years
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 30, 2023
Primary completion
Nov 18, 2024
Completion
Dec 17, 2024
Last update posted
Jan 19, 2025

2023 – 2024

United States locations

U.S. sites
36
U.S. states
15
U.S. cities
32
Facility City State ZIP Site status
Site 407 Escondido California 92025
Site 379 Gardena California 90247
Site 378 Huntington Park California 90255
Site 406 La Jolla California 92037
Site 373 Los Angeles California 90057
Site 387 Tarzana California 91356
Site 375 Torrance California 90502
Site 444 Edgewater Florida 32132
Site 015 Fort Lauderdale Florida 33312
Site 009 Atlanta Georgia 30303
Site 097 Atlanta Georgia 30318
Site 046 Covington Kentucky 41011
Site 061 Metairie Louisiana 70006
Site 377 New Orleans Louisiana 70112
Site 205 New Orleans Louisiana 70121
Site 410 Baltimore Maryland 21239
Site 394 Hyattsville Maryland 20782
Site 067 Boston Massachusetts 02115
Site 074 Ann Arbor Michigan 48109
Site 371 Las Vegas Nevada 89128
Site 070 Albany New York 12208
Site 411 Smithtown New York 11787
Site 181 Chapel Hill North Carolina 27514
Site 059 Wilmington North Carolina 28401
Site 436 Cincinnati Ohio 45219
Site 042 Cleveland Ohio 44195
Site 077 Columbus Ohio 43210
Site 195 Columbus Ohio 43215
Site 435 Grants Pass Oregon 97527
Site 049 Portland Oregon 97239
Site 456 Cedar Park Texas 78613
Site 370 Dallas Texas 75230
Site 408 Lufkin Texas 75904
Site 054 San Antonio Texas 78207
Site 369 San Antonio Texas 78229
Site 405 Seattle Washington 98108

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT05772169, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 19, 2025 · Synced May 19, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT05772169 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →